The third phase of clinical trials of cannabidiol showed the effectiveness of the drug as an adjuvant therapy for severe epilepsy. Treatment with cannabidiol reduced the number of seizures in drug-resistant patients with Lennox-Gastaut syndrome by almost half. The results of a randomized placebo-controlled trial have been published in the Lancet.
Up to four percent of epilepsy cases are caused by Lennox-Gastaut syndrome, a severe form of epilepsy that is accompanied by frequent seizures and cognitive impairment. It manifests itself in childhood and continues throughout life, and only a tenth of patients respond to modern methods of treatment, both drug and non-drug.
In a number of preliminary trials, cannabidiol (CBD) has been shown to have a significant anticonvulsant effect and is a promising antiepileptic agent. The English pharmaceutical company GW Pharmaceuticals has developed a drug based on 99% cannabidiol (Epidiolex) for the treatment of severe forms of epilepsy, including the Dravey syndrome of Lennox-Gastaut syndrome.
Dosage of CBD to reduce epileptic seizures
CBD is becoming increasingly popular after its curb properties were discovered. A 2018 report published in the journal Neuroscience, …
CBD may help you quit smoking cigarettes – study
We hear a lot of positive news about the power of cannabinoids and other compounds found in the hemp plant. One of the cannabinoids that attracted…
